ProCE Banner Activity

APHINITY: Interim OS Analysis of Adjuvant CT Plus Trastuzumab With vs Without Pertuzumab for Patients With HER2+ EBC

Slideset Download
Conference Coverage
Continued significant improvement in invasive disease–free survival but not OS evident with addition of pertuzumab to adjuvant chemotherapy plus trastuzumab in patients with HER2+ EBC with 6-year follow-up.

Released: December 16, 2019

Expiration: December 14, 2020

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen